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Abstract  
Warfarin is the most commonly used oral anticoagulant medication given as a 
prophylaxis and/or treatment of venous and arterial thromboembolic disorders.  
Warfarin doses vary up to 10-fold among patients due to pharmacokinetics, 
pharmacodynamics and pharmacogenomics factors. In addition, Warfarin has a low 
therapeutic index with the risk of developing serious side effects such as severe 
bleeding or failure of therapy. Therefore, the main challenge to achieve the 
therapeutic goal in Warfarin treatment is estimating the appropriate dose for each 
patient. It is estimated that pharmacogenomic factors contribute to more than 60% of 
dose variability. The gene encoding for the target enzyme of Warfarin, vitamin K 
epoxide reductase complex 1 (VKORC1), is a highly polymorphic gene and 
contributes to about 30% of this variability. The US Food and Drug Administration 
(FDA) recommends genetic testing to determine the VKORC1 genotype prior to 
using Warfarin. However, there are no data on VKORC1 alleles and genotypes or 
their frequencies among Emiratis. Therefore, the current approach is trial and error 
with warfarin doses which might lead to some serious complications for patients 
receiving this medication. In this thesis, we used PCR amplification and direct DNA 
Sanger sequencing to genotype the two most important variants in VKORC1 genes 
(namely, rs9923231 and rs7294). The sample consisted of 117 healthy Emirati 
nationals as control and 96 patients on stable Warfarin therapy. The alleles and 
genotypes frequencies were determined for both groups. In addition, the daily 
Warfarin maintenance dose for patients was examined for associations with the 
VKORC1 genotypes at the rs9923231 and rs7294positions. There was no significant 
difference in allele frequencies between the controls and patients for either SNP. The 
vii 
genotypes frequencies for rs9923231 were 25%, 48.4%, 26% for GG, GA, AA 
genotypes, respectively. In addition, genotypes frequencies for rs7294 variant were 
44%, 44%, 12% for GG, GA, AA genotypes, respectively. Crucially, both VKORC1 
polymorphisms were found to be strongly associated with the Warfarin doses 
required to achieve the target international normalized ratio INR (p < 0.0001). The 
results of this study confirm the suitability of VKORC1 genotyping to guide the use 
of the appropriate Warfarin dosage for Emiratis. 
Keywords: Warfarin dosage, rs9923231, rs7294, VKORC1, pharmacogenetics of 
Emiratis, Pharmacogenomics   
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 )cibarA ni( tcartsbA dna eltiT
بين مواطني الامارات  4927sr و   1323299srعلى الموقعين   1CROKV لجينتعدد الانماط الجينية 
 رات ذلك على جرعة عقار الوارفرينوتاثي
على جرعة   1CROKVالجينية في انزيم    هذه الدراسة تعنى بالصيدلة الجينية وذلك بدراسة تاثير المتغيرات
ج التخثرات الدموية وتسعى هذه الرسالة لمعرفة تردد أهم المتغيرات عقار الوارفرين وهو دواء شائع لعلا
الجينية في هذا الانزيم في مواطني دولة الامارات ودراسة حقيقة تأثير هذه الانماط الجينية في كل من موقع  
ومرضى يتم  111وطريقة عمل البحث تمت بجمع عينات  لامارتين اصحاء عدد   4927sr و   1323299sr
وذلك بعد موافقة الافراد المشاركين بالدراسة  وبعد جمع عينات الدم تم  96هم بعقار الوارفرين عدد علاج
استخلاص مادة الدي ان اي وعمل دراسة جينية عن طريق معرفة السلسلة الجينينه في كل من الموقع   
نتائج هذه لطبي   أدت واخذ معلومات عن جرعة المرضى اليومية من خلال ملفهم ا  4927sr و   1323299sr
% و  25.3هو   GGو كان تردد النمط الجيني ل  1323299srالرسالة بمعرفة تردد الانماط الجينية في موقع 
% ولم يلاحظ اي فرق بين تردد الانماط الجينية بين المرضى  93هو   AA% وتردد 69 AG تردد 
هو نفس تردد النمط الجيني % و99هو GG كان تردد النمط الجيني  4927srوالاشخاص الاحصاء وفي موقع 
% و للموقعين الجيني اثر كبير في تحديد الجرعة حسب  31كان الاقل بتردد AAوأما النمط الجيني  AG
كان له اثر اقوى بالتنبؤ بالجرعة مقارنة بالموقع الجيني   1323299srالتحليل الاحصائي للدراسة الا ان الموقع 
في دولة الامارات العربية  1CROKVلتحديد تردد الانماط الجينيةلانزيم  وتعد هذه اول دراسة 4927sr
 ودراسة اهمية هذا التغير في الانماط الجينية على المرضى الذين يتناولون عقار الوارفرين 5 
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CHAPTER 1: INTRODUCTION 
1.1 Human Genetic Variation and Drug Response 
Inter-individual variation in drug response and the development of drug side effects 
among patients are major challenges in clinical pharmacology. Several factors 
usually contribute to this variability including age, weight, level of organ function, 
co-medications, disease itself, concomitant diseases, cultural and racial factors 
including genetics, smoking, alcohol consumption and dietary preferences [1]. 
However, for some medications, the genetic variation is the major contributor with 
up to 95% in some cases [2].  
All humans are genetically identical in about 99% of their genomes. The 
approximately 1% differences from person to person are mainly in the forms of 
single nucleotide polymorphisms (SNPs), copy number variations (CNVs) and 
variation in the number of tandem repeats [3]. A SNP is a change in the sequence of 
a single nucleotide base[4]. On average, a SNP appears every 1250 bp of DNA in the 
human genome and they account for about 90% of human genetic variation  [3]. 
Generally, there are numerous polymorphic variants for most genes among the total 
world population and consequently it is often hard to know which variant is the 
“true” wild type sequence [5]. 
SNPs in coding genes of drug metabolizing enzymes, drug receptors, drug binding 
proteins and drug transporters may cause variability in the structures and/or activities 
of the encoded proteins [4]. In addition, in some instances SNPs in genes encoding 
drug-metabolizing enzymes or proteins involved in handling medications may result 
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in lower mRNA expressions and hence may cause lower enzymic activity or 
alteration in receptor function [6]. On the other hand, duplications or multiplications 
of active genes results in higher mRNA levels and thus higher enzyme expression 
that lead to an increase in enzymic activity and faster metabolism of the medications 
handled by that particular enzyme [6]. 
SNPs are responsible for a large proportion of the genetic contribution to variation in 
drug response and therefore they are key targets for pharmacogenetics and 
pharmacogenomics studies [4]. 
1.2 Pharmacogenetics and Pharmacogenomics 
Pharmacogenetics is the inherent response or the genetically determined variation in 
drug response. According to the FDA definition, it is the study of variation in DNA 
sequences that can affect drug response. Recently, the discipline of 
“pharmacogenomics” has been defined as the study of variation in DNA sequences 
and RNA characteristics at the whole genome level that can affect drug response. In 
other words, pharmacogenomics deals with inter-individual variation at whole 
genome level with specific expression products and functions that can be used to 
predict the appropriate treatment for individual patients [7]. To simplify the 
difference between pharmacogenetics and pharmacogenomics, pharmacogenetics can 
be defined as the effect of inter-indvidual differences caused by variation in a single 
gene whereas pharmacogenomics relates to the involvement of many genes or the 
whole genome in the variability in drug response [7] 
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To reiterate, genetic variation in genes encoding drug metabolizing enzymes, drug 
transporters, drug-binding proteins and receptors can all cause variation in the 
phenotypic response and thus are key targets for studying the pharmacogenetics and 
pharmacogenomics of most medications [8] 
Most efforts to study the involvement of genetic variation on dose requirements and 
responses of patients to drugs were carried out as a result of adverse drug reactions 
and side effects. These adverse drug reactions are estimated to be the 4
th
 or 6
th 
leading cause of death in the USA and to be the underlying cause of approximately 
10% of inpatient admissions to hospitals. It has been estimated that approximately 
2,216,000 patients suffer from serious side effects of medication leading to an 
estimated 106,000 patient deaths in the USA alone [9]. In the UK, adverse drug 
reactions cost approximately £380 million a year. In addition, an NIH report 
indicates that one out of ten inpatient admissions are for cases of adverse drug 
reaction [10]. 
Study carried out in Saudi Arabia showed that healthcare professionals lack the 
awareness of the importance of recording adverse drug reactions and analyze related 
the outcomes [11]. Another Study carried out in the United Arab Emirates (UAE) 
concluded the prevalence of inadequate knowledge of adverse drug reaction 
reporting procedures as a major barrier in recording adverse drug reactions [12]. 
More than 50% of adverse drug reactions relate to an administered dose [1] and 59% 
of drugs metabolized by polymorphic enzymes have been reported to have serious 
adverse effects [13]. 
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Therefore, pharmacogenetic and pharmacogenomics studies aim to reduce the risk of 
medication usage by predicting the optimal dose and the risk of developing side 
effects associated with particular medication in individual patients. In other words, it 
aims to identify patients at risk of developing adverse side effects by determining 
their genetic variants in the genes relevant to the proscribed medication [14]. 
Over the years, the genetically determined variation in drug response has become 
increasingly recognized by physicians, geneticists and pharmaceutical researchers. 
Therefore, there is an urgent need for pharmacogenetics and pharmacogenomics 
research to determine the appropriate dose for each patient. Consequently, 
pharmacogenetic testing may open the door for physicians to predict optimal doses 
and responses to individual medications given to patients. 
1.3 Warfarin: Historical Overview, Action Mechanism, Clinical Applications 
and Associated Side Effects 
In the early 1920s, an outbreak of unknown cattle disease was observed in the United 
States and Canada. Severe spontaneous hemorrhages occurred to cattle and some 
died after castration or dehorning. Prior to that, these procedures had been performed 
with no of excessive bleeding. Investigation autopsies of dead animals revealed that 
the animals bled to death [15]. One year later, a Canadian veterinary pathologist 
called Frank Schofield attributed the cause of death to the ingestion of hay made 
from spoiled sweet clover. Subsequent experimental testing on rabbits determined 
that spoiled clover worked as a potent anticoagulant [15]. 
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In 1929, another veterinarian called L.M. Roderick investigated the cause of bleeding 
and suggested that it was caused by the decrease in the function of prothrombin [16]. 
Subsequently, Henrik Dam from Denmark discovered that vitamin K deficiency can 
cause a hemorrhagic disease in chickens with lower prothrombin levels similar to the  
cases reported in cattle in North America [17]. Several years later, a trial was 
performed to make potent toxins out of spoiled sweet clover at Wisconsin University 
[18]. In particular, in 1933 Karl Paul Link and his team were able to isolate the toxic 
hemorrhagic substance [19]. Link and his group also identified the chemical structure 
of this compound as 3, 3,-Methylene-Bis-(4-Hydroxycoumarin) [20]. Link later 
named this compound Dicoumarol, which is a fermentation of the plant molecule 
Coumarin [21], that is present in many plants and gives the sweet smell of fresh grass 
and hay. Interestingly, the name “sweet clover” comes from its high content of 
Coumarin [18]. 
The Coumarin molecule itself has no anticoagulant properties but this activity results 
from its fermentation by fungi. Link donated the patents for Dicoumarol to the 
Wisconsin Alumni Research Foundation (WARF) in 1939 and continued his work on 
developing potent anticoagulants to be used as rat poison [21]. In 1940, he was able 
to achieve his goal with the most potent rodenticide which he named “Warfarin” 
[21].  It was believed that Warfarin would be extremely toxic to humans as well as 
rats until suicidal attempts in 1952 ended up with hospitalization followed by full 
recovery of the patient. Crucially, the patient was treated with Vitamin K to 
antagonize the effect of Warfarin [22].  Further studies demonstrated the possible use 
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of Warfarin as a treatment in coagulation conditions [21]. Numerous studies were 
carried out to establish the exact effects of Warfarin on humans [22]. 
Reports of variable responses by humans to fixed doses of Warfarin were 
documented very early after its initial use [23]. Today Warfarin is the most widely 
prescribed oral anticoagulant worldwide due to its effectiveness, low cost and 
convenient oral dose [24]. 
Vitamin K play a role in the coagulation cascade since the reduction of vitamin K 
leads to the activation of clotting factors through the gama carboxylation of these 
coagulation proteins mostly factors II (Prothrombin), VII, IX, X, protein C and 
Protein S. Understandably, these proteins are called Vitamin K dependent proteins. 
Once they are carboxylated, they get transformed into their active forms that lead to a 
coagulation cascade [25] . 
 Vitamin K reduced by Vitamin K expoxide reductase (VKOR) functions as a 
recycling enzyme for Vitamin K. The basic action mechanism of Warfarin is the 
inhibition of Vitamin K expoxide reductase (VKOR) enzyme and thus the impairing 
of the synthesis of clotting factors [26], as illustrated in Figure 1. 
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Figure 1. Effect of Warfarin on VKORC activity and Vitamin K cycle. [26].  
 
There are two isomer forms of Warfarin, the S and the R isomers as shown in Figure 
2. The S-isomer is five times more potent than the R-isomer in inhibiting VKORC 
[25]. 
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Figure 2. Molecular Structure of (A) S -Warfarin and (B) R- Warfarin. [27]. 
The effect of Warfarin therapy on a blood coagulation profile is measured by the 
International Normalized Ratio (INR) which is a universal conversion of 
prothrombin time test [28].  
 
 
 
 
(A) S –Warfarin (B ) R- Warfarin 
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 In 1990, the INR was adopted as an indicator to monitor Warfarin effects. INR 
corrects for variation that come with different thromboplastin reagents from different 
hospitals and laboratories worldwide, and for new batches of reagents [29].  
To avoid hemorrhage (the principal adverse side effect of Warfarin), frequent 
monitoring and adjustment to the anticoagulant effect of the drug is necessary. 
 This depends on the INR result, which can be obtained by a Prothrombin Time test 
(PT test) for monitoring and evaluating the effect of vitamin K antagonist (VKA) 
therapies and is a reliable measure of extrinsic pathways of coagulation [29], [30]. 
 In order to achieve treatment goals with anticoagulation therapy using a Vitamin K 
antagonist such as Warfarin, patients need to maintain their target INR range. This 
goal can be achieved with regular monitoring and appropriate adjustment to a 
Warfarin dose [30]. Target INR intervals vary according to Warfarin indication, but 
in general an INR value of <2.0 is associated with increased risk of a thrombotic 
event while INR value of >4.0 is associated with increased risk of a bleeding crisis. 
Therefore, current recommendations suggesting an INR range of between 2.0 and 3.0 
for patients with atrial fibrillation and venous thromboembolism [30], [31] and an 
INR range of 2.5-3.5 for patients with mechanical heart valves [32]. 
Warfarin does not exert an instant effect as an antithrombotic/anticoagulant 
medication as several doses are required to show an effect. The delayed effect is due 
to pre-existing Vitamin K-dependent clotting factors that must be catabolized by the 
body while at the same time inhibiting the activation of newly made Vitamin K-
dependent clotting factors and for total protection from thrombus formation or 
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complications. However, the orally administered anticoagulant Warfarin can be 
given with a rapid acting anticoagulant such as Heparin or Low Molecular Weight 
Heparin [30]. 
Warfarin is an oral anticoagulant that is mostly prescribed to prevent the progression 
or recurrence of acute deep vein thrombosis or pulmonary embolism as a second 
option after using Heparin. It is also used to prevent venous thromboembolism 
during surgeries such as orthopaedic or gynecologic surgeries and as a prophylactic 
treatment in chronic atrial fibrillation, acute myocardial infarction, prosthetic heart 
valve and stroke [29], [31]. 
Although it is widely used, Warfarin has one major limitation.  It is a drug with a low 
therapeutic index and is listed among the top 10 agents associated with serious side 
effects such as bleeding. Approximately 20% of patients using Warfarin suffer from 
bleeding, thromboembolic events (TEE), inpatient hospitalization and emergency 
admission or sometimes treatment failure and the complication of coagulation. It 
should always be given with safety controls as indicated on the drug label [29], [33]. 
Besides hemorrhages, other minor side effects have been observed such as skin 
lesions and necrosis. Another problem associated with Warfarin use is the numerous 
drug-drug interactions and its teratogenic effect. Therefore, Warfarin should never be 
used during pregnancy due to associated birth defects and abortion [29].  
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1.4 Factors Influencing Variability in Warfarin Dose Requirements  
Variability in warfarin doses has been extensively documented. This variability can 
be attributed to combinations of genetic and non-genetic factors as detailed in the 
following sections. 
1.4.1 Non-Genetic Factors 
As already mentioned, Warfarin is a drug with a low therapeutic index and therefore, 
small increases in dosage may cause serious side effects while a lower than 
therapeutic dose will be ineffective. Maintenance doses of Warfarin required to 
safely achieve stable anticoagulation can vary across populations by up to twenty 
fold with an average dose of 5 mg/day. However, some individuals require doses of 1 
mg/day or less whilst others may require up to 20 mg/day or even more to achieve 
the desired INR target [29]. The identification of the maintenance dose is important 
to avoid the risk of bleeding that comes with Warfarin use, depending on the co-
morbid conditions of the patient [34]. Significant efforts and research have been 
undertaken to avoid the development of side effects by estimating the exact safe 
dosage as Warfarin is the most often cited reason for mortality caused by medication 
[33]. It is also the second leading cause of drug emergency admissions in the United 
States [35]. It is worth noting that the most often cited life-threatening complications 
of Warfarin use are gastrointestinal bleeding and intracranial hemorrhage [36]. 
Many co-medications can change the required dose of Warfarin and the main 
mechanism is either by induction or inhibition of hepatic CYP2C9 or by competition 
with the plasma protein binding site for Warfarin [29]. Drugs that can induce the 
expression of CYP2C9 cause an increase in the enzymic action of CYP2C9 and 
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possibly the induction of other metabolizing liver enzymes [37]. examples of such 
drugs include alcohol, barbiturates, glutethimide, grisofulvin, rifampin, 
carbamazepine, phenobarbital, phenytoin and the herbal antidepressant st. john`s 
wort. Chronic alcohol consumption has the same action on CYP2C9 enzymic 
induction [29]. Patients using enzyme inducer drugs along with Warfarin require 
higher doses of Warfarin [38]. 
Other medication may cause the opposite effect on the CYP2C9 enzyme as they may 
inhibit its catalytic activity [38]. For example, azole antifungal medications (e.g. 
fluconazole and voriconazole), amiodarone, sulfamethoxazole (found in the common 
combination antibiotic trimethoprim-sulfamethoxazole), statins (e.g. fluvastatin and 
lovastatin), and some antidepressants (e.g. fluvoxamine and sertraline), cimitdine, 
chloramaphenicol, cotrimoxazol, disuulfiram, metronidazole, phenylbuazone, and 
acute alcohol intoxication all have inhibitory effects on CYP2C9. Patients using a 
CYP2C9 inhibitor medication concomitantly with Warfarin need lower doses of the 
anticoagulant since the metabolism and the evacuation of Warfarin will be reduced 
as a result of the decrease in CYP2C9 function and thus increase the risk of an 
accumulation of Warfarin to toxic levels. In these cases, anticoagulant overdose is a 
major risk. In terms of drug-drug interactions, among all these medications, the drugs 
with a strong effect on Warfarin dosage are amiodarone and statins [39], [40], [29].  
In order to predict Warfarin dosage the Warfarin dosing website 
(www.warfarindosing.com) developed an online calculator that takes into account 
possible factors that can cause changes in Warfarin dosage especially concomitant 
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therapy with amiodarone, statins, azole antifungals, sulfamethoxazole and 
trimethoprim as factors to predict the most appropriate Warfarin dose [29]. 
Vitamin K deficiency, a hepatic disease that impairs a synthesis of clotting factors, 
any disease or medication that can impair organ function that controls Warfarin 
metabolism, or a hypermetabolic state that elevates Vitamin K levels depending on 
clotting factors and catabolism are all factors that can contribute to a 
hypoprothrombinemic state in patients and therefore they affect the required dose 
[29]. 
Warfarin is a water soluble molecule that is quickly absorbed after oral intake with 
peak plasma concentration obtained from 60 to 90 minutes and 100% bioavailability 
with little individual variation in bioavailability. However, food may delay 
absorption without affecting the extent of absorption and 99% is bound to plasma 
albumin and drugs with a higher affinity to a binding site for albumin like 
sulfonamides that can displace Warfarin from Plasma albumin leading to an 
elevation of Warfarin activity [29]. In addition, Lovastatin and Indomethacin 
compete with Warfarin for plasma protein binding sites and therefore increase the of 
free  activity of Warfarin and potentiate its action [29].  
1.4.2 Genetic Factors 
There are several genetic factors that can affect a patient’s Warfarin dose. 
Polymorphisms in cytochrome P-450 C9 (CYP2C9), the enzyme responsible for 
Warfarin metabolism, are major contributors. However, it was estimated that genetic 
variation in the gene encoding for this enzyme account for approximately 12% of the 
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changes in the maintenance dose of Warfarin [41],[42]. In addition, genetic variation 
of VKORC1, the gene encoding Warfarin site of action (Vitamin K Epoxide 
Reductase), account for up to 30% of the inter-individual variation in maintenance 
doses [43], [44]. More details on the contribution of VKORC1and CYP2C9 will be 
provided in the next section (1.5.).  
Researchers attempted to identify other genes involved in the dose variation of 
Warfarin among individuals identified CYP4F2 as a contributory factor to variations 
in dose. The CYP4F2 enzyme is widely distributed in human livers and other tissues.  
Its function is to catalyze the hydroxylation of Lipoxygenase-derived eicosanoids as 
well as the oxidation of Vitamin K [45].  A genetic variation in CYP4F2 that results 
in the replacement of a valine amino acid at position 433 by methionine (p.V433M) 
leads to a decrease in the oxidation of Vitamin K. This in turn causes an elevation in 
the concentration of vitamin K in hepatic cells and therefore patients on Warfarin 
with this variant needs higher doses [46].  The total effects of CYP4F2 on Warfarin 
dosage accounts for about 1-2% of the change in dose among individuals [47]–[49]. 
Studies on GGCX gene found a correlation of a microsatellite variant with Warfarin 
sensitivity [26]. This enzyme has a critical role in the vitamin K cycle as it catalyzes 
the gamma carboxylation of vitamin K dependent proteins in the coagulation cascade 
as shown in Figure 3. 
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Figure 3. Role of γ-glutamyl carboxylase (GGCX) in Vitamin K cycle [50]. 
GGCX catalyzes the posttranslational carboxylation of specific glutamic acid 
residues to γ-carboxyglutamic acid (gla) in a variety of vitamin K–dependent 
proteins [50]. 
This gene is located on chromosome 2 and encodes for gamma-glutamyl carboxylase 
enzyme (GGCX). Variants in GGCX require about 6% reduction in Warfarin dosage 
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and the total effect of GCCX gene accounts for <1% of the variation in Warfarin dose 
requirements [51].  
Genotype information and clinical factors such as age and weight are important 
predictors in Warfarin dosing calculations to select the optimal dose for the patients 
at the start of therapy [52]. 
A different Vitamin K intake for each patient is also a factor in Warfarin sensitivity 
and resistance. A high intake of vitamin K reduces the response to the medication 
[53]. In general, Vitamin K refers to a family of vitamins K1 (Phylloquinone) and K2 
(Menaquinone) that are mainly involved in human health and disease [54]. Vitamin 
K1 comes from dietary sources such as the green leaves of some vegetables, 
vegetable oils and supplements. The majority of Vitamin K stores in the human body 
consist of Vitamin K1 [55].  
In addition, gut bacteria synthesize Vitamin K2 which has a limited role in providing 
the human body with daily requirement of Vitamin K in comparison to Vitamin K1. 
There are four main fat soluble vitamins (A, D, E and K). Vitamin K has the lowest 
total stores in the body hence several weeks of  restricted dietary intake of Vitamin K 
can completely deplete all the Vitamin K stores in the body [53]. Studies on the 
effects of different Vitamin K intake levels on Warfarin requirements found that it is 
a significant contributor to variation in the initial Warfarin dose [56]. 
17 
1.5 The Pharmacogenetics and Pharmacogenomics of Warfarin 
1.5.1 Cytochrome P450 Enzymes 
Metabolic elimination of most current drugs is largely mediated by the function of 
cytochrome P450 proteins. This enzyme system is encoded by many genes. The 
enzymes expressed are mainly found in the liver and they play key roles in drug and 
other xenobiotic metabolisms [57]. The CYP system is very important for the 
detoxification process as it eliminates foreign substances. In addition to their 
involvement in the metabolism of lipophilic compounds involving oxidation, the 
CYP system is involved in the metabolism of endogenous substrates such as sterols, 
steroids, eicosanoids, serotonin, bile acids, Vitamin D, retinoid, fatty acids and 
uroporphyrogens  [57]. 
In every species there are 270 cytochrome P450s (CYPs). However, only 57 CYP 
genes and 33 pseudogenes are found in the human genome. These are organized in 
18 families and 42 subfamilies. of all the CYP families only 3 families (families 1, 2 
and 3) are responsible for drug metabolism. CYP2C9 constitutes approximately 
18% of the total CYP protein content in the human liver [38], [58]. 
CYP2C9 is one of the most important enzymes in drug metabolism as it metabolizes 
approximately 60 drugs. There are inter-ethnic and inter-individual variations in drug 
metabolisms with the occurrence of genetic polymorphisms in the CYP2C9 gene 
[59]–[61]. CYP2C9 is involved in the metabolism of 10-20% of all the clinically 
important drugs worldwide such as Warfarin and other coumarin anticoagulants, 
losartan, tolbutamide, sulfonylurea drugs, angiotensin ii blockers, nonsteroidal anti-
inflammatory drugs (NSAIDS), Phenytoin and glipizide [47], [60], [61]. 
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There are four distinctive groups of CYP phenotypes arranged according to their 
metabolic capacity.  Extensive metabolizers (EM) with regular metabolic capacity, 
low metabolizers (LM) with  low metabolic activity, intermediate metabolizers (IM) 
that shows intermediate activity, while the ultra-rapid metabolizers (UM) show the 
highest metabolic activity group [62]. 
CYP2C9 polymorphisms are important determinants of the Warfarin dosage as the 
presence of CYP2C9 polymorphisms is associated with a reduction in the metabolism 
of S-Warfarin [63], [64]. Thirty four CYP2C9 variant alleles have been reported in 
the world population so far (http://www.cypalleles.ki.se/).  CYP2C9*1 is a wild-type 
allele, and there are two important single nucleotide variations that result in missense 
mutations in the coding region of the CYP2C9 gene. The CYP2C9*2 allele (C430T 
in exon 3) results in the replacement of an arginine at the amino acid position 144 by 
cysteine (p.R144C).  
This is a functionally important substitution as this mutation leads to the reduction of 
the catalytic activity to 12% compared to the wild-type enzyme. Additionally, the 
CYP2C9*3 allele (A1075C of exon 7) leads to the substitution of a leucine residue 
by isoleucine at position 359 (p.L359I). This mutation is associated with a reduction 
in the catalytic activity to about 5% of the wild type. Studies have shown that the 
CYP2C9*3 allele is associated with lower intrinsic clearance of the Warfarin 
substrate and a lesser enzyme activity (<5%) than CYP2C9*2. Both CYP2C9*2 and 
*3 genetic variants are widespread in caucasian populations, with allele frequencies 
varying from 3.3% to 18% [65], [66].  
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As above, both CYP2C9*2 and *3 variants encode for enzymes with reduced 
catalytic activities that result in impaired hydroxylation of Warfarin compared to the 
wild-type CYP2C9 enzyme. Therefore, lower doses of Warfarin are required in 
individuals with these alleles. It was observed that a longer time is required to 
achieve a stable Warfarin dosage and therefore these patients are at higher risk 
during the initial phase of Warfarin therapy [47], [63]. 
In caucasian populations the frequency of the CYP2C9*1/*1 genotype is 65-70%, the 
CYP2C9*1/*2 genotype is 15-20%, the CYP2C9*1/*3 genotype is 8-10%. Poor 
metabolizer genotype frequencies for CYP2C9*2/*2, CYP2C9*3/*3 and 
CYP2C9*2/*3 are between 1 and 2% each [63], [64]. 
1.5.2 Vitamin K Epoxide Reductase (VKORC1) 
The Vitamin K epoxide reductase VKOC1 enzyme is involved in the biosynthesis of 
Vitamin K dependent coagulation factors through the Vitamin K regeneration 
process. On the other hand, Vitamin K plays a key role as a cofactor in gamma 
carboxylation of several clotting factors (II, VII, IX and X) and proteins C and S that 
are all involved in coagulation. The Vitamin K epoxide reductase VKOC1 enzyme is 
Warfarin sensitive and can be inhibited by preventing the Vitamin K recycling 
process [67]–[69] as shown in Figure 4. 
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Figure 4. Warfarin effect as Vitamin K anticoagulant. [44] 
Warfarin inhibits Vitamin K recycling and thus preventing the formation of more 
Vitamin K dependent coagulation factors [44].  
The VKORC1 gene encodes the vitamin K epoxide reductase complex subunit-1, a 
small transmembrane protein of the endoplasmic reticulum. VKORC1 [MIM 
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608547] is the key enzyme of the Vitamin K cycle and the molecular site for the 
action of Vitamin K antagonists (Coumarins) including Warfarin, Acenocoumarol 
and Phenprocoumon, which are used for long-term treatment of thromboembolic 
diseases [44], [70]. 
It has been known for many years that the action of Warfarin involved Vitamin K yet 
without full understanding of the exact nature of its involvement until 2004. The 
exact molecular target of Warfarin was discovered by two independent research 
groups when they found a protein that was later named as Vitamin K epoxide 
reductase complex subunit 1 (VKORC1) [68], [71].  This gene is located on 
chromosome 16p11 as shown in figure5. 
 
Figure 5. Chromosomal  location of  VKORC1 gene on the short arm of  
chromosome 16. [72]. 
The first group of researchers, Li and colleagues tested the ability of candidate genes 
to inhibit vitamin K epoxide reductase (VKOR) activity in human cells by using 
short interfering (siRNA) pools against these genes to observe gene activity. Li and 
colleagues expressed the gene in insect cells and described the gene as coding for a 
163-amino acid protein with 3 exons. They also showed that the protein contained 1 
to 3 transmembrane domains and 7 cysteine residues, 5 of which are conserved 
among human, mouse, rat, zebrafish, Xenopus, and Anopheles [68]. 
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In same the year, Rost and colleagues cloned the VKORC1 gene and described it as a 
gene encoding a protein of 163 amino acids with a mass of 18KDa [69]. It was 
mainly expressed in fetal and adult livers and to a lesser extents in fetal hearts, 
kidneys, lungs, adult hearts and the pancreas. The enzyme is associated with the 
endoplasmic reticulum [71]. 
Rost colleagues also studied the involvement of VKORC1 in the combined deficiency 
of Vitamin-K-dependent clotting factor type 2 (VKCFD2; OMIM 607473), and 
resistance to Coumarin oral anticoagulant drugs (Warfarin resistance, WR; OMIM 
122700). They found that it correlated with pathological conditions and Warfarin 
resistance [69]. In the rat, four heterozygous missense mutations in VKORC1 were 
reported in Warfarin resistant cases. In addition, one homozygous point mutation in 
exon 3 has been found in two unrelated index cases of a combined deficiency of 
vitamin K-dependent clotting factor type-2 (VKCFD2) [69].  
They also studied the over expression of wild-type VKORC1 and the form carrying 
the VKCFD2 mutation and noticed a marked increase in VKOR activity and 
increasing Vitamin K production by approximately 14 to 21 times compared with 
untreated or mock-transfected cells [68], [69].  These discoveries helped in the 
understanding of Warfarin resistance in humans and rodents.  
The purification of recombinant human VKORC1 protein from baculovirus-infected 
insect cells was reported in by Chu who demonstrated that it was possible to convert 
Vitamin K epoxide to Vitamin K; and Vitamin K to reduced Vitamin K through the 
enzymatic function of a single VKORC1 polypeptide [73]. It was thought that 
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VKORC1 was subunit 1 of the enzymatically functional complex involved in 
Vitamin K recycling.  However, it was found that the gene product of VKORC1 was 
enzymatically active on its own which led to the informal shorting of the name to 
VKOR [74]. 
Genetic variations in VKORC1 was associated with significant inter-individual and 
inter-ethnic variability in the dosage of Vitamin K antagonists (Coumarin) [75]. 
Studies on VKORC1 enhanced our understanding of the Vitamin K cycle and led to 
improved clinical practice [76]. 
1.6 The Global Prevalence of the Clinically Relevant VKORC1 Alleles and 
Genotypes 
It is well known that Warfarin dosage and responses are greatly affected by genetic 
variation in the VKORC1 gene. In addition, genetic variation in this gene results in 
different phenotypes such as resistance to Warfarin (Warfarin resistance, WR) or 
pathological conditions known as multiple coagulation factors deficiency type 2 
(VKCFD2) that can cause a rare bleeding disorder [69], [77].  
The discovery of a haplotype structure in the human genome and the ability to define 
SNPs, facilitated genotyping studies at significantly reduced costs.  There is a need to 
take into account not only differences between the genotypes of individuals but the 
differences in genotypes between different populations to improve health care [78]. 
In Warfarin resistant patients, several rare mutations in the VKORC1 gene lead to 
amino acid changes in VKORC1 proteins. These rare mutations are not reported in 
the general population [69]. 
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The genetic basis of the large inter-individual variability among Warfarin patients 
investigated by Rieder, who described the coding region variants of VORC1 that are 
highly detrimental and cannot explain Warfarin dosage variation [79] . 
In addition, a study was conducted to determine whether polymorphisms in non-
coding regions of the VKORC1 contribute to variability in the maintenance dose of 
Warfarin and found that SNPs in non-coding regions are associated with Warfarin 
dosages across the normal dose range (2 to 10 mg per day) [79]. This opened the 
door to further study other regulatory polymorphisms in the VKORC1 that could 
possibly change Warfarin dosage requirements. Consequently, SNPs in the VKORC1 
non-coding region were found in various populations [79], as illustrated in figure 6.  
 
Figure 6. VKORC1 gene structure with the relevant non-coding variants.  
The mechanism of how these SNPs in non-coding affect Warfarin dosage variability 
were thought to be through the effect on the mRNA levels [79].  
The first SNP (C6484T, rs9934438 (608547.0008) or 1173C>T) was reported to 
associate with low Warfarin doses. This SNP is located in the first intronic region of 
the VKORC1 gene and the wild type C/C genotype requires significantly higher 
doses compared to the T/T genotype [43]. 
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This variant is in near perfect linkage disequilibrium with promoter region variant 
G3673A (rs9923231) [43]. Since the frequency of C6484T is approximately similar, 
if not identical, to the frequency of G3673A, some researchers consider this variant 
inert but it is still used frequently in haplotype determination of the VKORC1 gene as 
marker of SNP [52]. 
Warfarin sensitivity in patients with lower doses is frequently associated with 
promoter region single nucleotide polymorphism -1639G-A (608547.0006). On the 
other hand, VKORC1 variant rs7294 (G9041A), or 3730G>A are reported to be 
associated with Warfarin resistance in patients who need higher doses compare to the 
wild type [66]. 
Two SNPs in the non-coding region of the VKORC1 gene, rs9934438 (608547.0008) 
and rs9923231 (608547.0006), were the best predictors of Warfarin dosage through 
transcriptional mechanisms that alters expressions of the Warfarin target receptor 
VKORC1 [79]–[81] 
The-1639G-A (rs9923231) variation is associated with lower Warfarin dosages, 
Warfarin sensitivity and higher risks of bleeding [66]. Individuals with the A/A 
genotype (group A, haplotype 2* mainly) required a lower dose than those with the 
A/G or G/G genotypes. The G allele comes with a 44% increase in activity when 
compared with the A allele [82]. 
The rs7294 (G9041A), is a variant associated with high warfarin dosages that occurs 
at the 3′UTR of VKORC1 gene [43], [83]. It does not usually occur with the 
1173C>T and 3673G>A variant allele haplotype [43]. 
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A patients with (rs9923231) and 1173T (rs9934438) variant allele was reported to 
have a low dose of about 24-26 mg/week while patients with wild type required a 
dose of 36mg/week [26].   
A high dosage reported for patients with (rs7294) allele variants of approximately 40 
mg/week as a mean dose [26], [83]. This indicates the effect of VKORC1 in non-
coding variants on Warfarin pharmacodynamics studies that concluded that VKORC1 
variation can explain 25% of the variability in Warfarin dosage [79]. 
 A significant correlation of the relevant SNPs in the VKORC1 with approximately 
30% of Warfarin dosage variation has been determined in a genotyping study of 201 
patients using Warfarin. These findings indicate that the VKORC1 genetic variation 
plays a greater role in dose requirements compared to CYP2C9 which explains only 
12% of the variation in dose requirements [26]. SNPs in non-coding regions of the 
VKORC1 gene classify Warfarin patients according to their required dose of 
Warfarin to safely achieve the target INR [79].  
According to this classification, patients with SNP (rs9923231) have low Warfarin 
dose-requirement with approximately 2.7 mg per day for the A/A genotype that is 
mostly distributed in Asian Americans. High dosage groups with rs7294, A/A 
genotype need 6.2 mg per day which is widely distributed among African Americans 
and an intermediate dose of 4.9 mg per day for patients with heterozygosity in both 
SNPs (rs7294 and rs9923231) [79]. There are continuous efforts to identify VKORC1 
haplotypes but the nomenclature is still varied [79].  
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1.7 Warfarin Usage in the UAE 
There are a limited number of clinical research studies on Warfarin usage in the UAE 
and no pharmacogenetics studies so far. There was a study in 2012 conducted in Al-
Ain to evaluate patient and staff compliance with Warfarin usage guidelines and to 
assess the overall practice and patient outcome [84]. The authors reported that at Al-
Ain Hospital, each year there are 800 cases (~27 new) of patients on Warfarin 
including Emiratis and expatriates. Indications for Warfarin usage among those 
patients were 35% for atrial fibrillation, 28% for deep vein thrombosis, 20% for 
prosthetic heart valves and 12% for stroke and dilated cardiomyopathy.  
The authors found that regular INR monitoring was carried out for only 23% of the 
patients. They also found that 73% of the patients had a stable INR while 20% had a 
high INR and 7% had lower values than the therapeutic target. 22% of patients have 
been admitted to the emergency ward from Warfarin patients with 9% of the cases 
unrelated to Warfarin use. In addition, side effects such as abnormal bleeding have 
been frequently reported among patients with a high INR. Furthermore, hematemesis 
was reported for 25.3%, shaving cuts for 21.8%, bleeding gums for 19.9%, bleeding 
wound for 14.6% and melena in 11.3% of the patients [84]. 
A lack of genetic studies related to Emiratis on Warfarin prompted us to carry out 
this project. 
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CHAPTER 2: STUDY RATIONALE, AIM AND OBJECTIVES  
2.1 Rationale 
Warfarin is a drug with a low therapeutic index where small dose changes may result 
in serious side effects or treatment failure. It is well known that the genetic makeup 
of the individual contributes to their response to medication including Warfarin. A 
significant proportion of patients receiving the standard dose of Warfarin may either 
not respond to treatment or exhibit bleeding as a side effects. Genetic variations in 
the VKORC1 gene play a major role in Warfarin dosages and are responsible for 
about 30% of the dose variation. Therefore, it can be considered to be the major 
genetic determinant. Despite their importance for determining the optimal starting 
dose for patients, no genetic studies have been carried out on Emiratis in relations to 
Warfarin use. Therefore, the purpose of this thesis is to start to fill this gap in our 
knowledge for the local Emirati population.   
2.2 Aim and Objectives 
2.2.1 Aim  
Identify the alleles and genotypes frequencies among Emiratis for two important 
SNPs (rs9923231 and rs7294) in the VKORC1, the gene encoding the cellular target 
for Warfarin treatment.    
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2.2.2 Objectives 
To achieve the above aim, the thesis objectives are:  
1. Recruit and obtain blood samples from healthy Emirati donors and patients 
receiving Warfarin as part of their healthcare. 
2. Isolate and quantify genomic DNA from each subject using standard molecular 
techniques.  
3. Genotype those samples for two SNPs, rs9923231 and rs7294 SNPs, in the 
VKORC1 gene using PCR and direct Sanger DNA sequencing. 
4. Determine the SNPs allele and genotype frequencies among healthy Emiratis 
subjects and patients receiving Warfarin.  
5. Correlate the determined allele and genotype frequencies with drug response in 
patients. 
6. Generate genetic data that might be deposited/ shared with health care providers in 
the UAE and/or with international databases.  
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CHAPTER 3: MATERIALS AND METHODS  
3.1 Blood Sampling  
Blood samples were collected from two groups: the first group consisted of 96 
unrelated UAE nationals who suffered from a coagulation disorder and are being 
treated with Warfarin as part of their care. This group of subjects was recruited from 
patients attending the INR clinic at Tawam Hospital, Al-Ain, UAE. The second 
group consisted of 117 healthy Emirati subjects from Al-Ain and Abu Dhabi.  
All the individuals had read the information sheet and signed informed consent forms 
to participate in the study. About 10ml of peripheral venous blood was collected. 
Five ml of the blood sample was placed in an EDTA tube (containing an 
anticoagulant) to be genotyped. The subjects also completed a questionnaire and 
their medical files were reviewed to examine the fulfillment of the 
inclusion/exclusion criteria. This study protocol was carried out at the laboratories of 
the College of Medicine and Health Sciences at UAE University. In addition, it was 
approved by the ethical committee for human research in the Al-Ain District (CRD 
261-Protocol No. 13/38). 
3.2. Extraction of DNA from Peripheral Leukocytes 
Deoxyribonucleic acid (DNA) was extracted from an ethylene-diamine-tetra- acetic 
acid (EDTA)-anticoagulated blood using a whole blood extraction kit (Flexigene 
DNA isolation kit (250)- Applied Biosystems). The isolated genomic DNA was 
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stored in sterile vials at 4 
o
C until analyzed. DNA samples were kept at – 20 oC for 
long term storage. 
3.3. Primers Design 
Primers for amplifying the relevant parts of the VKORC1 gene were designed using 
primer3 http://primer3.ut.ee and were custom made by Metabion Inc 
(http://www.metabion.com). The list of PCR and sequencing primers are listed in 
Table 1. 
SNP Forward Primer Reverse Primer 
rs9923231 3`GCCAGCAGGAGAGGGAAATA5 3`AGTTTGGACTACAGGTGCCT5` 
rs7294 3`GGCTTACGCACGTATTCC5` 3`GGTTCAGACTTGGCTGATTG5` 
 
Table 1. Sequences of the oligonuceloetide primers used for the PCR amplification 
and genotyping of the two VKORC1 SNPs 
3.4 Polymerase Chain Reaction (PCR) 
 
PCR amplification (thermal cycling) conditions were as follows: a single 
denaturation cycle of 5 minutes at 95 
o
C followed by 40 cycles of 95 
o
C for 2 
minutes. The exact annealing temperatures and times are listed in table 2 and then at 
72 
o
C for 2 minutes. This was followed by a single cycle of 7 minutes at 72 
o
C.  
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Primer Name 
Annealing 
Temperature (
o
C) 
Annealing Time 
(Sec) 
Product  Size 
(pb) 
 rs9923231 58 30 290 
 rs7294 60 45  659 
Table 2. Annealing temperatures optimization and expected product sizes.  
3.5 Analysis of PCR Amplicons by Agarose Gel Electrophoresis . 
 
The two VKORC1 specific products (amplicons) from each subject were separated 
by 0.6% agarose gel electrophoresis to ensure a good DNA quality was produced 
before sequencing. The  promoter region SNP (rs9923231) is expected to produce  
DNA band (A)of 290 bp whereas SNP (rs7294) will give a Size of 659 bp (B) as 
presented in Figure 7  
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Figure 7. Agarose electrophoresis analysis of representative PCR reactions for the 
two SNPS and  primers of experiment and their approximate base pairs sizes. 
3.6 DNA Sequencing  
DNA was sequenced using a dideoxy sequencing (chain termination of Sanger) 
method with a 3130Xl Genetic Analyzer (applied Biosystems). The procedure 
involved cleaning up the PCR reactions using an Exo-SAP-IT treatment prior to 
Sanger DNA sequencing. 
3.6.1 ExoSap-IT Treatment 
The ExoSAP–IT was used for cleaning up the PCR products. This technique has 
been shown to be suitable for cleaning up PCR products of less than 100 bp to over 
than 20kb without any sample loss, by removing the unused excess primers and 
nucleotides through a degradation by enzyme action.  The method in this experiment 
was carried out by 1.25 l of purified PCR product to undergo enzymatic purification 
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with 0.5 µl of an ExoSAP –IT enzyme mixture at 37 oC for 15 minutes. This was 
followed by heating at 80 
o
C for 15 minutes to inactivate the exonuclease and SAP 
enzymes. 
3.6.2 DNA Cycle Sanger Sequencing  
The cycle sequencing was carried out by preparing a sequencing mix containing 1l 
(3.2 pmol) of sequencing primers, 4l of ready reaction premix 2.5X (Big Dye 
Terminator Cycle Sequencing Kit Applied Biosystems), 1 l of BigDye Terminator 
v.3.1 sequencing buffer (5X) and 20ng/ ml template, miliQ water was added to form 
20l reaction. The tubes were placed in a thermal cycler and an initial denaturation 
step was performed with a rapid thermal ramp to 96 
o
C for 1 minute, then the 
following steps were repeated up to 25 cycles: 
 A.rapid thermal ramp to 96 oc  (96 oc for 10 seconds). 
 A rapid thermal ramp to 50  oc (50 oc for 5 seconds). 
 A rapid thermal ramp to 60 oc (60 oc for 4 minutes). 
 A rapid thermal ramp to 4oc. 
 Purification of the sequencing products.  
3.6.3 DNA Sequencing Purification Step 
If the dye terminators are not removed completely before the electrophoresis step, the 
signal from the dyes will be obscured due to an excess of DNTPs.  This method is 
suitable when using Big Dye Terminators v3.1 as it produces consistent signaling 
and it is good at getting a 20l sequencing reaction in 96-well reaction plates 
following a brief spinning after removing the reaction from the thermal cycler. 5l of 
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125 mm EDTA is added to the 60 l of 100% ethanol in each well and the mixture is 
sealed and inverted 4 times before being incubated for 15 minutes at room 
temperature. This was then immediately centrifuged at 3000 xg for 30 minutes 
(Sigma 2-16 pk) and the plate was inverted and spun at up to 185 xg then removed 
from the centrifuge.  A 60 l of 70% ethanol was also added to each well then spun 
again at 1650 x g for 15 minutes with the centrifuge set at 4 
o
C. This was followed by 
inversion and spinning up to 185xg for 1 minutes before removal from the 
centrifuge. 
3.6.4 Formamide Treatment  
Hi-Di Formamide is a highly deionized formamide formulated with stabilizers and 
ready for use as an injecting solvent in DNA analysis methods. The samples were 
resuspended in 15 μl formamide (Hi-Di TM formamide, Applied Biosystems), 
denaturated at 95 
o
C for 2 minutes and then kept on ice for 2 minutes until 
sequencing.  
3.6.5 Sequencing Data Interpretation and Genotype Calling  
For each patient the chromatograms of the nucleotide sequence were aligned with the 
original VKORC1 sequence (ENST00000394975) using the chromas lite program in 
order to detect the presence of SNPS/mutations as well as to define each patient`s 
genotype. 
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3.7 Statistical Analysis  
SSPS and Graph Pad programs were used to apply selected statistical analysis; we 
used chi-square tests for non-parametric variables to compare between frequency 
results, while multiple linear regression models, ANOVA and Spearman analysis 
were used to study dose-genotype relations.  
37 
CHAPTER 4: RESULTS  
4.1 Description of Study Sample 
This study involved two groups of UAE nationals. The first group included 117 
unrelated healthy subjects as controls and the second group consisted of 96 patients 
who were on Warfarin treatment for at least two months. Patient characteristics are 
summarized in table 3. 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Characteristics of the recruited patients 
Informed consent was obtained from each participant. This study was approved by 
the ethics committees of each participating institution. Patient information (indicators 
of Warfarin use, maintenance doses and INR values etc.) were collected from 
Tawam Hospital medical records as of 23/09/2014. 
 
Age 
Median Age 64  year 
Average Age 59  year 
Standard Deviation (SD) 19.73 year 
Gender 
 
Male 48(50%) 
Female 48(50%) 
Indication of 
Warfarin 
Atrial Fibrillation 46(48%) 
Deep Vein Thrombosis 15(16%) 
Valve Replacement 26(27%) 
Antiphospholipid Syndrome 3(3%) 
Cardio Vascular Shunt 1(1%) 
Cerebella Ataxia 1(1%) 
Artery Thrombosis 1(1%) 
Pulmonary Embolism 2(2%) 
Valve Disease 1(1%) 
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In this study we recruited equal numbers of patients of both genders: 48 females and 
48 males. The mean age was 64 and the median age was 59. The age ranged from 17 
to 99 years with a standard deviation of 19.73 years.  
Warfarin was prescribed for patients for different pathological conditions with Atrial 
Fibrillation (AFIB) at 48%; Deep Vein Thrombosis (DVT) at 15%; Antiphosholipid 
Syndrome (APS) at 3%; After Mitral Valve Replacement (MVR) and Aortic Valve 
Replacement (AVR) for 27%; 2% for Pulmonary Embolism (PE), while Valve 
Disease, Arterial Thrombosis, Cerebella Ataxia, Cardio Vascular Shunt each 
constituted 1% of the total use of Warfarin.  
The target INR range for 67% of the patients was 2.5-3.5; 32% with an INR target 
range of 2 -3 where only 1% have a target range of 1.5-2.  
The average Warfarin dosage of patients was 4.7 mg/day with an SD of 2.47 and a 
median dose of 4.5 mg/day. The highest dosage was 15 mg/day and the minimum 
dose was 0.5 mg/day.  
4.2.  VKORC1 Genotype and Allele Frequencies 
Using PCR amplification and direct DNA sequencing, we genotyped each subject 
from both groups for two VKORC1 gene variants relevant to Warfarin dosage. The 
two variants are the promoter region variant rs9923231 and the 3` UTR region 
variant rs7294, as listed in table 9.  
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SNP 
 
Nucleotide position Nucleotide 
change 
Gene region 
Genomic  cDNA 
rs9923231 3673 c. -1639 G>A Promoter 
rs7294 9041 492+134 G>A 3'-region 
 
Table 4. Description of the studied polymorphisms (SNPs) of the VKORC1 gene. 
(cDNA: coding DNA, rs: reference subgroup) 
Rs7294 was selected as per the literature due to its key role in Warfarin resistance 
cases, while variant SNP rs9923231 was selected as per the USA Food and Drug 
Administration (FDA) recommendations [85]; as shown in table 5. 
 
Drug Link in 
Drugs@FDA 
 
Referenced Subgroup 
Labeling Sections with  
Pharmacogenomic  Information 
      Warfarin 
 
VKORC1 rs9923231 
A allele carriers 
 
Dosage and Administration 
Clinical Pharmacology 
 
 
Table 5. Food and Drug Administration (FDA) labeling recommendations for 
Warfarin 
4.2.1 Determination of the VKORC1 rs9923231 Genotypes and Alleles 
Frequencies 
VKORC1 rs9923231 SNP genotype and allele frequencies among patients and 
controls are presented in table 6. 
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Table 6. Genotypes and alleles frequencies among patients and controls for 
rs9923231 .(N indicates the total number of study subjects in both controls and 
patients) 
 
We compared the percentage of the three genotypes (GG, GA and AA) between both 
groups (control and patients) as listed in table 1 
 
 
 
Table 7. Percentage of rs9923231 SNP Genotypes among both groups, controls and  
patients. 
(N indicates the total number of study subjects in both controls and patients) 
  
  
Controls 
N=117 
(%) 
Patients 
N=96 
(%) 
UAE 
N=213 
(%) 
Genotypes 
GG 30(25.6) 24(25) 54(25) 
GA 58(49.6) 46(47.9) 104(49) 
AA 29(24.8) 26(27.1) 55(26) 
Alleles 
 
G 118(50.4) 94(49) 212(49.8) 
A 116(49.6) 98(51) 214(50.2) 
Patients 
n=96 
Controls 
n=117 Genotype 
44.4% 55.6% GG 
44.2% 55.8% GA 
47.3% 52.7% AA 
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There are no statistically significant differences in the prevalence of GG, GA, AA 
genotypes for rs9923231 between the control group and the patients. We used a chi-
square test to investigate (chi-square= 0.1459, df = 2, p-value = 0.9296). The aim of 
this test was to investigate if there was a difference in genotype frequencies between 
healthy control groups and patients. 
The genotype frequencies of rs9923231 in the 213 UAE participants are presented in 
(table 9). They show that the genotypes GG and AA have similar distributions of 
25% and 26% respectively. On the other hand, the heterozygous genotype GA 
frequency was 49 %. The allele frequencies for rs9923231 variants are presented in 
Table 9 with almost equal frequencies of 49.8% for the G allele and 50.2% for the A 
alleles.VKORC1 rs9923231 SNP genotype frequencies among patients and control 
subjects are presented graphically in Figure 8. 
 
Figure 8. Graphical presentation of genotype frequencies among patients and control 
for rs9923231.  
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In addition, we compared the results from this study to data from other populations 
as listed in table 8 
 
VKORC1 
SNP 
 
 
Genotype 
UAE 
n=213 
 
 
Saudi 
n=131 
[86] 
 
   
Iran 
n=81 
[87] 
 
 
China 
n=178 
[88] 
 
 
Caucasian 
n=22 
[89] 
 
Indian 
n=43 
[90] 
 
G-1639A 
GG 25 37.4 15.8
7 
0.6 31.8 83.8 
GA 49 39.7 57.1
4 
15.7 50.0 9.50 
AA 26 22.9 26.9
8 
83.7 18.2 6.80 
Alleles 
Frequency 
G 49.8 57 44.4 8.42 56.82 88.4 
A 50.2 42.7 55.6 91.57 43.18 11.6 
 
Table 8. Ethnic distribution of rs9923231 Genotypes and alleles in various 
populations. 
The graphic representation of ethnic distributions of rs9923231 genotype  
frequencies is shown in figure 9 and allele frequencies in figure 10 
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Figure 9. Ethnic distribution of rs9923231 genotypes 
 
 
 
Figure 10. Ethnic distribution of the rs9923231 alleles 
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We used a chi-square test (nonparametric test for discrete variables) to compare the 
differences between  the allele frequencies in populations shown in table 8; the value 
of p<0.05 was considered as statistically significant. Statistical analyses were 
performed applying the Graph Pad program.The UAE population when compared to 
the Chinese Population had a p value of <0.001. The UAE population when 
compared to the Indian Population had a p of <0.001. For the other populations, there 
were no significance differences in allele frequencies 
4.2.2 Determination of the VKORC1 rs7294 Genotype and Allele Frequencies 
VKORC1 rs7294 SNP genotype and allele frequencies among patients and control 
subjects are presented in table 9..  
 
 
 
 
 
 
 
 
 
 
Table 9. Genotype and Allele frequency for rs7294 for controls and patients. 
  
We compared the percentage of the three genotypes (GG, GA and AA) for rs7294 
between both groups (control and patients) as listed in table 11. 
SNP Genotype 
Controls 
N=117 
(%) 
Patients 
N=96 
(%) 
UAE 
N=213 
(%) 
G9041A 
 rs7294 
GG 54(46.2) 40(41.7) 94(44) 
GA 46(39.3) 48(50) 94(44) 
AA 17(14.5) 8(8.3) 25(12) 
Alleles 
Frequency 
G 154(66) 128(66.7) 282(66) 
A 80(34) 64(33.3) 144(34) 
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Table 10. Percentage of rs7294 SNP genotypes among both control and patient 
groups. 
 (N= total number of subjects in both control and patient groups) 
 
Figure 11. Graphic presentation of genotype frequencies among patients and control 
subjects for rs7294. 
 
The genotype frequency of rs7294 for  the total study sample of 213 UAE locals  is 
shown in table 6. It shows differences in the distribution of the homozygous GG and 
AA genotypes with frequencies of 44% and 12%, respectively. On the other hand, 
Patients 
n=96 
Controls 
n=117 
Genotype 
42.6 % 57.4 % GG 
51.1 % 48.9 % GA 
32.0 % 68.0 % AA 
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the heterozygous GA genotype is in equal distribution with the homozygous 
genotype 44 %. Allele frequencies are shown in table 9 with the G allele being 
present at frequency of 66% ,while the A allele is present at  a frequency of 34%. We 
compared results from this study to data from other populations as listed in table 11. 
 
 
VKORC1 
SNP 
Genotype 
UAE 
n=213 
 
Chinese 
n=551 
[91] 
Caucasian 
n=22 
[89] 
Indian 
n=43 
[90] 
G9041A 
rs7294 
GG 99 81.3 43.5 8.1 
GA 99 18.3 47.8 18.9 
AA 13 0.4 8.7 73 
Alleles 
Frequency 
G 66 90.5 67.4 18.6 
A 34 9.5 32.6 81.4 
 
 
Table 11. Ethnic distribution of the rs7294 genotypes and alleles frequencies. 
 
Graphic representation of ethnic distribution of rs7294 genotype frequencies is 
shown in figure 12 and the allele frequencies in figure 13.  
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Figure 12. Ethnic distribution of rs7294 genotypes 
 
Figure 13. Ethnic distribution of rs7294 alleles. 
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We used a chi-square test (nonparametric test for discrete variables) to compare the 
differences between the allele frequencies in populations as shown in table 11.The 
value of p<0.05 was considered as statistically significant. Statistical analyses were 
performed applying the Graph Pad program.  
The UAE population when compared with the Indian and Han-Chinese population 
had a p<0.001.There were no significance differences in allele frequencies with 
European populations. 
4.3 The Rs9923231 and Rs7294 VKORC1 Variants Genotypes Associated with 
Warfarin Doses Among Emirati Patients  
 A Spearman correlation coefficient statistical analysis was selected to test the 
correlation coefficient in each SNP.  
We used the Graph Pad to study the correlation between each SNPs and the daily 
maintenance Warfarin dose for patients included in this study. In summary, both 
SNPs shows significant correlations with dosages (P<0.05) as shown in figures 14 
for rs9923231 genotypes and figure 15 for rs7294 genotypes. 
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Figure 14. Spearman Correlation Coefficient between rs9923231 genotypes and daily 
Warfarin dosage.  
 
 
Figure 15. Spearman Correlation Coefficient between rs7294 genotypes and daily 
Warfarin dose. 
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We used a scatter Plot to graphically represent each genotypes relation to dosage. 
Both SNPs were correlated significantly to daily Warfarin dosage (P-value<0.05) as 
shown in figures 16 and 17.  
 
 
Figure 16. Scatter Plot representation of rs9923231 genotype relation to daily 
Warfarin dose (*** means P-value < 0.05). 
 
The GG genotype shows a higher dosage compared to GA and a lesser dosage to the 
AA genotype. While for rs7294 the higher dose is associated with the AA genotype.  
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Figure 17. Scatter Plot representation of rs7294 genotype relation to daily Warfarin 
doses (*** means P-value < 0.05). 
 
In addition, we used a Boxplot method to represent patient dose variation in relation 
to genotype and to show the dispersion (the spread) of doses among each genotype 
for SNPs. This data is shown in figures 18 and 19.  
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Figure 18. Boxplot of mean daily Warfarin doses for different VKORC1 genotypes 
(SNP rs9923231).  
 
The horizontal line indicates the median; the box covers 25–75% percentiles. Points 
outside this show up as outliers. In all 96 individuals were genotyped for rs9923231 
genotyping. The maintenance dose of Warfarin was related significantly to genotype 
since AA genotype required a lesser dose compared to the intermediate dose for a 
GA genotype and a relatively higher dose compared to the GG genotype. 
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Figure 19. Boxplot of mean daily Warfarin doses for different VKORC1 genotypes 
(SNP rs7294). 
 
 The horizontal line indicates the median, the box covers 25–75% percentiles. Points 
outside this show up as outliers. In all 96 individuals were genotyped for rs7294 
genotyping. The maintenance dose of Warfarin was related significantly to genotype 
since GG genotypes required a lesser dose compared to an intermediate dose for GA 
genotypes and a relatively higher dose for AA genotype carrying patients5 
Furthermore, we used a multiple liner regression analysis, where daily Warfarin 
dosages in milligrams (mg) was the dependent variable and the genotype was an 
independent variable and controlling for other factors such as age and gender. Using 
VKORC1 rs9923231 genotypes, age, and gender. 
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Linear regression analysis shows that there is significant relationship between the 
rs9923231 SNP genotypes (AA, GA and GG).  
The average dose for AA genotypes is (2.61 mg /day SD 1.022), for the GA 
genotype it is (4.74 mg/day SD 1.72) and for GG genotype it is (7 mg/day SD 2.796). 
the average age of patients was 59 (SD 19).  
We found that there was a significant relationship between age and dosage (P-value 
< 0.01) but to a lesser extent than for genotype while no relationship with gender to 
daily Warfarin dose (P-value = 1). This data is shown in table 12.  
  
 
 
 
 
 
 
 
Table 12. Multiple linear regression models with rs9923231 genotypes, age, and 
gender. 
(Multiple R-squared: 0.477, adjusted R-squared: 0.4541, degree of freedom (DF): 91,  
p-value: 3.518e-12. F-statistic: 20.75) 
 
For rs7294 we also used a multiple linear regression model and results are shown in 
table 12 
 
 
 
Variable Daily dose P value 
AA < 0.001 
GA < 0.001 
GG < 0.001 
Age < 0.01 
Gender 1 
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Table 13. Multiple linear regression models with rs2794 genotypes, age, and gender. 
)Multiple R-squared:  0.2797, adjusted R-squared:  0.248, F-statistic: 8.832 on 4, p-
value: 4.525e-06(. 
 
Using a linear model where dose is the dependent variable and rs2794 genotypes are 
the independent variable, and controlling for other factors such as age and gender, we 
found that there was a significant relationship between the rs7294 SNP genotype and 
the dose taken (P-value = 0.0003). The average Warfarin dose required for the GG 
genotype is 3.6 mg/day (SD 2.5), the GA genotype is 5.3 mg/day (SD 2) and for the 
AA genotype it was 6.7 mg/day (SD 2.6). Age significantly correlated to dose (P-
value >0.001) while gender was found not to be correlated (P>1). 
  
Factors Daily dose P-Value 
GG >0.001 
GA >0.001 
AA >0.001 
Age >0.001 
Gender 1 
56 
CHAPTER 5: DISCUSSION AND CONCLUSIONS  
Allele and genotype frequencies for SNPs rs9923231 and rs7294 in the VKORC1 
gene were found to be in a Hardy-Weinberg equilibrium among the study sample of 
213 UAE nationals. There were no significance differences in the prevalence of GG, 
GA and AA genotypes for rs9923231 variants between the patients and control 
groups as determined by a chi-square test  (p-value = 0.9296). Similarly there was no 
significant difference between the two group for the rs7294 variant (chi-square test 
for GG, GA and AA genotypes (p-value = 0.1842). This means, as expected, that 
both SNPs distributed equally between control and patient groups without any 
significant difference associated with any pathological condition. 
The genotype frequency for the rs9923231 variant in the total study sample of 213 
local UAE participants for homozygous GG and AA are presented in Figure 8 and 
Table 9. They show similar distributions of 25% and 26% respectively while the 
distribution of the heterozygous GA genotype was higher at 49%. Allele frequencies 
for rs9923231 are shown in Table 6 and indicate no differences in G and A allele 
frequencies at 49.8% and 50.2%, respectively. 
The genotypes frequency for the rs7294 variant in the total study sample of 213 
subjects is shown in table 9 and indicates some differences in the distribution of 
homozygous genotypes (GG and AA) of 44% and 12%, respectively, while the 
heterozygous GA genotype is in equal distribution with homozygous genotype at 
44%. We found that the allele frequency for G (66%) more than for the A allele 
(34%) as shown in table 9.  
Warfarin dosages vary among Emirati patients with doses ranging from 0.5 mg to 15 
mg of Warfarin per day (figure 16, and figure 17).  This wide variation in dose 
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requirements is a major justification for carrying out this type of genetic study among 
Emiratis.  Genetic causes are likely to be contribution factor in a significant 
proportion of this variability, as demonstrated by many studies on Warfarin dosage 
[92]. Genotypes for VKORC1 SNPs correlate significantly with daily Warfarin doses 
according to the results of this study (figures 14 and15). The rs9923231 and rs7294 
are closely associated with dosage with a p-value of < 0.001 for both SNPs (figures 
14 and15). Therefore, we can conclude that the rs9923231 and rs2794 are good 
predictors of Warfarin maintenance dosage as shown in the Boxblot analysis in 
figures 18 and 19.  For the rs9923231 homozygous AA genotype a smaller dose is 
required (2.6 mg/day, SD 1.022) compared to the heterozygous GA genotype (4.75 
mg/day, SD1.7). A higher dose is required for the homozygous GG genotype (7 
mg/day, SD 2.7) with a P-value < 0.0001(3.518e-12). 
A recent study in Al- Ain evaluated the effects of other factors such as age, gender, 
body mass index (BMI), indications of Warfarin treatment, patient compliance in 
maintaining stable INR indicators of correct dosage, etc. They found that gender, and 
BMI have no effect while age, co-morbid status, and compliance were found to 
significantly affect the coagulation profile of patients [84].  Although age and gender 
both have been studied in previous studies, we included it in this study to show have 
direct effect on dosage but not on INR. In our study age significantly affected 
Warfarin dosage as demonstrated by the multiple regression model of analysis (tables 
12, 13). Gender on the other hand had no significance effect (table 12, 13).  
Generally there is a focus on rs9923231 (-1639 G/A) variant which is located at the 
second nucleotide of an E-box (CANNTG) of the 5` untranslated regions (5`UTR) of  
the VKORC1 gene [82]. This variant plays a key role on the activity of the promoter 
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region of the VKORC1 gene and it is believed to be a causative SNP for low dose 
requirement phenotypes in some patients [52]. The activity of the G allele is 44% 
higher than the A allele in this position [82]. Polymorphism in rs9923231(-1639 
G/A)  shows an interference with  the mRNA expression in liver samples since it is 
associated with variable levels of mRNA. The A allele disturbs the binding of 
transcription factors  to the VKORC1 gene promoter region leading to a decrease in 
active mature copies of the VKORC1 protein activity [82]. 
According to the literature, patients with the G allele require a daily dose of 5 
mg/day compared to 3.5-3.7 mg/ day for patients with the A allele [26].  In our study 
daily doses of Warfarin were approximately 2.6 for homozygous patients with the A 
allele and approximately 7 mg/day for patients with the homozygous G allele 
(Figures 16 and 18). 
Another study has reported that patients with the A allele have a Warfarin dose 
ranging from 2.9 up to 3 mg per day, while patients with the homozygous G allele 
range from 5.5 up to 6 mg/day [79].  
The frequencies of the rs9923231 (-1639 G/A) genotypes and alleles have been 
widely studied in different populations [52].  For example, 90% of the Asian 
population have the A allele and therefore patients of Asian origin require lower 
doses of Warfarin [52]. On the other hand, 40% of some caucasian populations have 
the A allele. It was postulated that rs9923231 is the best predictor of Warfarin dose 
requirements especially in the initial stages of Warfarin therapy [79].  
It is worth mentioning that the rs9923231 variant is the only SNP mentioned in FDA 
recommendations for labeling Warfarin leaflets amongst all the other important 
SNPs in the VKORC1 gene. However, many studies have shown the importance of 
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other non-coding SNPs in the VKORC1.  However, these SNPs are mostly in perfect 
linkage disequilibrium with rs9923231 [79]. Based on several studies, the FDA has 
recommended genetic testing on Warfarin for the VKORC1, rs9923231, A allele 
carriers and for the CYP2C9 gene haplotype  
(http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083
378.htm) [85].  
Another SNP located in the 3′UTR of theVKORC1 rs7294 or as it called in the 
literature G9041A, or 3730G>A. It is not correlated with any other SNP in  
theVKORC1 gene [79].  Generally this SNP is not found in the same haplotypes as 
the G3673A. This is the reason for selecting this SNP in our study although it was 
not recommended by the FDA. Patients with rs7294 alternative variants may require 
higher doses of Warfarin  [43].  
In this current study, rs7294 as shown in figure 15 and figure 17 for the homozygous 
AA genotype, required higher doses (6.7 mg/day, SD 2.6), while the heterozygous 
GA genotype required 5.3 mg/day, (SD 2) a lesser dose was required for 
homozygous GG genotypes (3.61 mg/day SD 2.5) With a P-value of  < 0.0001 
(0.0003).  Therefore, findings in this study support previously published data 
confirming a higher dose requirement for individuals with the homozygous A allele 
genotype (5.7 mg/ day) [26]. 
It was suggested that 6-37% of the variation in Warfarin dosage among individuals is 
due to SNPs in the VKORC1 gene [79], [81], [85]. It was well documented that the 
VKORC1 polymorphism highly influences Warfarin dosage and in some cases may 
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cause resistance at the A allele in  rs7294 variants or sensitivity with A alleles of the 
rs9923231 variant  [79], [81]. 
This is first genetic study among Emiratis regarding VKORC1 allele and genotype 
frequencies. Our data suggests that SNPs are very important for Warfarin 
maintenance dosage and therefore they are likely to be of clinical significance 
(Figures 14 and 15). 
Different ethnic groups require different Warfarin doses. For instance Chinese 
individuals, on average, require lower dose compared to African Americans [93], 
[94]. 
There have been many trials on new medication to replace Warfarin since its 
approval in 1954. This is mainly because of the many reports of side effects observed 
in patients receiving this medication. However, surveillance studies on complications 
and pharmaco-epidemiology of Warfarin are not currently available in the UAE. 
There is generally a lack of drug-drug and food-drug interaction studies locally. For 
instance, it was not easy to find reported cases of side effects associated with 
Warfarin treatment, such as Inpatient hospitalization due to Warfarin, patient’ 
outcomes in selecting a dosage of Warfarin depending on non-genetic factors in 
Emiratis.  Our data indicates that genotyping will be useful and most probably cost 
effective when initiating Warfarin treatment.  
The two variants tested are useful but a clearer and more accurate picture can be 
observed if other parts of the VKORC1 gene and CYP2C9 gene are studied in more 
depth in Emiratis. It is also important to look at non-genetic factors involved in 
Warfarin dose  requirements among  Emiratis such as lifestyle, diet, chronic use of 
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other medications, food supplements and herbal remedies used by the local 
population.    
Our data indicates that pharmacogenetic testing of rs9923231 and rs7294 variants is 
highly relevant to the maintenance of Warfarin dosage among Emirati patients on 
this medication. Implementation of genetic testing, at least for these two variants, is 
likely to have a direct effect with potential benefits to the patients and healthcare 
system in UAE. This is also likely to have a direct impact on patient safety and 
reduce suffering and cost.  
The evidence provided here demonstrates that genetic factors in the VKORC1 gene 
are significant contributors to Warfarin dosage and, as a result may be employed to 
reduce the risk of developing side effects such as bleeding or thrombosis.   
Having said that, we believe that it is important to sequence the rest of the VKORC1 
gene to study the haplotypes and perhaps examine for the presence of private variants 
in this gene among Emiratis. It is also important to study the variants of the CYP2C9 
gene.  
In conclusion, this is the first study reporting the influence of genetic factors such as 
VKORC1 polymorphisms (rs9923231 and rs7294) in Emiratis. We also report the 
frequencies of alleles and genotypes of these SNPs allowing us to compare with 
other populations which might be useful for genealogical studies.   
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